Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bukwang Pharmaceutical Co., Ltd. (003000:KRX), powered by AI.
Bukwang Pharmaceutical Co., Ltd. is currently trading at ₩4,775. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bukwang Pharmaceutical Co., Ltd. on Alpha Lenz.
Bukwang Pharmaceutical Co., Ltd.'s P/E ratio is 37.5.
“Bukwang Pharmaceutical Co., Ltd. trades at a P/E of 37.5 (premium valuation) with modest ROE of 4.3%.”
Ask for details →Bukwang Pharmaceutical Co., Ltd. is a key player in the pharmaceutical industry engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Established in South Korea, the company focuses on producing medications that address various therapeutic categories, including neurology, gastroenterology, and infectious diseases. Bukwang is committed to advancing healthcare through innovative solutions and has invested significantly in R&D efforts aimed at developing proprietary drugs and novel treatments. The company's products cater to both domestic and international markets, impacting medical practitioners, healthcare institutions, and patients globally. Bukwang Pharmaceutical holds a significant position in the healthcare sector due to its emphasis on scientific research and development, strategic collaborations with global pharmaceutical entities, and efforts to expand its presence in emerging markets. Its contributions are crucial for addressing unmet medical needs and enhancing the quality of life for patients by providing access to effective and safe pharmaceuticals.
“Bukwang Pharmaceutical Co., Ltd. trades at a P/E of 37.5 (premium valuation) with modest ROE of 4.3%.”
Ask for details →Bukwang Pharmaceutical Co., Ltd. (ticker: 003000) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 606 employees. Market cap is $471.1B.
The current price is ₩4,775 with a P/E ratio of 37.52x and P/B of 1.38x.
ROE is 4.30% and operating margin is 7.06%. Annual revenue is $200.7B.